Compare Match Group Inc (MTCH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Match Group Inc trades at $41.48 (market cap $9.37B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 13.7× Match Group Inc's market cap, and Match Group Inc pays a 1.96% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Match Group Inc for 115 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| MTCH | VRTX | |
|---|---|---|
Market Cap | $9.37B | $128.16B |
Volume | 2,544,041 | 806,603 |
Sector | Media | Health |
52-Week High | $44.40 | $557.96 |
52-Week Low | $28.90 | $407.37 |
Typical Hold Time | 115 Days | 120 Days |
Enterprise Value | $12.34B | $122.29B |
Dividend Yield | 1.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $40.86, up 0.59% today, with a bullish technical signal and strong cash flow growth. The company reported a net income margin of 20.17% for 2025, with recent earnings beats in Q4 2025 and Q2 2026. Revenue remains stable at $3.49B, while analyst consensus is a Buy with a $42.29 price target. Positive sentiment is driven by margin expansion and Hinge's growth, though high debt levels and mixed quarterly results present some caution.
The outlook for MTCH is cautiously optimistic, with upside to the consensus target offering ~3.5% potential gain. Strengths include robust profitability, solid cash generation, and product innovation, but risks involve elevated debt, competitive pressures, and reliance on Tinder's turnaround. Investors should weigh strong fundamentals against execution risks in a dynamic dating app market.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
